# Tirzepatide Dosage: FDA-Labeled Titration Schedule and Trial Protocols

> Tirzepatide dosage: starts at 2.5 mg once weekly, titrated to 5, 7.5, 10, 12.5, or 15 mg. FDA-labeled titration schedule, half-life, subcutaneous injection route — trial-documented.

## The short version

Tirzepatide dosage is stepped up slowly to give the body time to adjust and reduce nausea. Here is the plain-English version of how the trials dosed it and what the FDA label documents.

It starts low — 2.5 mg once a week — and increases by 2.5 mg every four weeks as tolerated. The goal is a maintenance dose of 5, 10, or 15 mg per week, depending on the indication and individual tolerance. The highest dose studied and approved is 15 mg per week. It is injected once a week, under the skin (subcutaneous), on the same day each week.

The reason once-weekly dosing works is structural: a lipid tail on the molecule binds to albumin (a protein in blood), slowing how fast the body clears it. The elimination half-life is approximately 5 days — meaning roughly half the dose remains in the system after five days — which is long enough to maintain an effect between weekly injections.

Everything below is from the FDA label and published trial protocols, reported as labeled and documented — not a personal dosing recommendation. A licensed clinician makes prescribing decisions.

## Tirzepatide dosage — the FDA-labeled titration schedule

The once-weekly subcutaneous dosing schedule documented in the FDA label and used across the phase 3 trials follows a stepwise titration [6]:

- Weeks 1–4: 2.5 mg once weekly (starting dose, not a maintenance dose)
- Weeks 5–8: 5 mg once weekly
- Weeks 9–12: 7.5 mg once weekly
- Weeks 13–16: 10 mg once weekly
- Weeks 17–20: 12.5 mg once weekly
- Week 21 onward: 15 mg once weekly (maximum)

The trial maintenance doses studied in the phase 3 efficacy arms were 5, 10, and 15 mg (participants escalated to those target doses over the 20-week titration period). Dose escalation may be slowed if tolerability is a concern; that decision rests with the prescribing clinician [6].

For the obesity/chronic weight management indication, the same titration schedule is used. For the type 2 diabetes indication, the approved dose range is the same 5–15 mg once weekly, with 2.5 mg as the starting dose. The sleep apnea trial programme (SURMOUNT-OSA) used 10 or 15 mg as maintenance doses [11, 12].

The SURPASS programme also included a head-to-head arm against semaglutide 1 mg using 5/10/15 mg tirzepatide doses [3]. SURPASS-CN-MONO in Chinese patients with early type 2 diabetes used the same 5/10/15 mg dose arms and found HbA1c reductions of −2.04/−1.93/−2.02% vs placebo at 40 weeks [27].

## Tirzepatide injection — subcutaneous administration

Tirzepatide injection is administered subcutaneously — under the skin, not intravenously or intramuscularly. Approved and studied injection sites are the abdomen, thigh, and upper arm. In the trial programme, the route was subcutaneous in all efficacy and safety studies [1, 4, 5].

The prescribing label recommends rotating injection sites to reduce injection-site reactions (redness, itching, tenderness, occasional bruising or small lumps), which are among the more commonly reported adverse effects in both trials and post-market surveillance [8, 22].

The formulation is a subcutaneous solution supplied in a pre-filled pen; the specific pen device is a prescription product. Refrigerated storage is required for the marketed formulation. Specific reconstitution and storage parameters are formulation-dependent and outside the scope of the published efficacy literature [1].

Oral formulations of related incretin agents exist for other compounds, but subcutaneous injection is the only route in the approved tirzepatide programme.

## Tirzepatide dose — pharmacokinetics and half-life

The approximately 5-day elimination half-life that supports once-weekly tirzepatide dosing comes directly from the molecule's design. A C20 fatty diacid moiety (eicosanedioic acid) — a lipid tail — is attached via a glutamic acid linker and two spacer units to a lysine side chain on the peptide. This lipid arm binds to albumin, a blood-plasma protein with a long circulating half-life. The albumin binding slows renal clearance and protects the peptide from enzymatic degradation, extending its residence time in the bloodstream to approximately 5 days [1].

This is the same strategy used by fatty-acid-modified selective GLP-1 receptor agonists to achieve once-weekly or even monthly dosing. A key pharmacokinetic study (Urva et al., Diabetes Obes Metab, 2020) found that tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists, with the effect attenuating with continued dosing [15].

The ~5-day half-life also means the drug remains in the system for several half-lives after the last dose. This has clinical implications for dosing pauses around surgery or pregnancy — a decision for the prescribing clinician.

For older adults, a post hoc analysis of SURPASS trials found that hypoglycaemia incidence stayed consistent in adults with type 2 diabetes regardless of background insulin or sulfonylurea use, suggesting the glucose-dependent insulin mechanism holds across age groups [19].

## Tirzepatide reviews — what the clinical literature says about tolerability

Two systematic sources summarise the tolerability profile across the trial programme:

**GI tolerability.** A meta-analysis of nine RCTs (Zeng et al., Front Endocrinol, 2023) examined pancreatitis and gallbladder/biliary disease. Pancreatitis risk was not significantly increased (RR 1.46, 95% CI 0.59–3.61); the composite gallbladder or biliary disease outcome was significantly increased (RR 1.97, 95% CI 1.14–3.42) [7]. A separate meta-analysis in obesity without diabetes across 13 trials found overall GI adverse events approximately 2.94-fold elevated versus placebo (RR 2.94, 95% CI 2.61–3.32) for tirzepatide [13]. A pharmacovigilance analysis of FAERS data (Shen et al., PLoS One, 2026) documented patterns of GI adverse event reporting including nausea, vomiting, diarrhoea, constipation, and the sulfur-burp/belching signal [2].

**Efficacy versus dulaglutide.** A meta-analysis (Qazi et al., Healthcare, 2026) found greater glycaemic and weight efficacy versus dulaglutide, with discontinuation due to adverse events approximately 32% higher with tirzepatide — a tolerability-efficacy trade-off described as clinically established [26].

**Real-world FAERS safety.** An analysis of FAERS data 2022–2025 (Almansour et al., Healthcare, 2025) found incorrect dose administration was the single most frequently reported event, underscoring the importance of correct titration and injection technique [22].

Cost context: the tirzepatide cost to patients varies substantially by indication, insurance status, and whether a patient uses a manufacturer savings programme. That information is outside the scope of this research digest; current pricing information is available from pharmacy benefit managers and the manufacturer.

---

A step-by-step reading of the tirzepatide trial record — the dual-incretin mechanism, the SURPASS/SURMOUNT/SUMMIT evidence, and the safety signals — summarised and cited, by a publisher that prescribes nothing.